stockrow
Saturday 7 November 2026
Export DMRA’s income statement to Excel — free account
Galecto, Inc.
DMRA Healthcare Biotechnology
- EPS
- +78.1%
- Free cash flow
- −877.5%
Quarter to September 2026, against a year earlier
23.67
1.81
+8.28%
Follow DMRA
Alert me
Galecto, Inc. (DMRA) P/E ratio
As of 6 November 2026, Galecto, Inc. (DMRA) trades at a P/E ratio of 24.7×. Over the past ten years it has ranged from 0.0× (September 2026) to 24.7× (November 2026) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 10.6× and in line with the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 24.7×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| TSHA Taysha Gene Therapies, Inc. compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| DMRA Galecto, Inc. | 24.7× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)